首页 > 过刊浏览>2025年第25卷第4期 >2025,25(4):594-599. DOI:10.3980/j.issn.1672-5123.2025.4.13
上一篇 | 下一篇

联合治疗视网膜静脉阻塞性黄斑水肿的研究进展

Research progress in combined treatment of retinal vein occlusion-induced macular edema

发布日期：2025-03-20
  • 摘要
  • 访问统计
  • PDF预览
  • 参考文献
  • 相似文献
  • 引证文献
    [关键词]
    [摘要]

    视网膜静脉阻塞性黄斑水肿(RVO-ME)作为视网膜静脉阻塞最威胁视功能的并发症之一，具有难治性、顽固性和反复性的特点。近年来研究发现，联合治疗优于单一治疗，既能有效减轻黄斑水肿，又能在一定程度上改善视功能，同时减少治疗次数，降低总体费用，减轻患者负担等，弥补了单一治疗模式的不足，被临床寄予厚望。文章旨在对视网膜静脉阻塞性黄斑水肿的联合治疗现状及展望作一综述。

    [Key word]
    [Abstract]
    Retinal vein occlusion-induced macular edema(RVO-ME)is a severe complication of retinal vein occlusion, known for its challenging treatment, persistence, and tendency to recur. Recent studies have demonstrated that combined therapy offers advantages over single therapy, effectively reducing macular edema, enhancing visual function, decreasing the frequency of treatments, lowering overall costs, and easing the patient's burden. This approach addresses the limitations of single treatment methods and has garnered significant clinical interest. This article reviews the current status and future prospects of combined treatments for RVO-ME.
    [基金项目]
    山东省自然科学基金面上项目(No.ZR2023MH069); 潍坊市科技局课题项目(No.2021YX029)
    \〖1\〗 Romano F, Lamanna F, Gabrielle PH, et al. Update on retinal vein occlusion. Asia Pac J Ophthalmol, 2023,12(2):196-210.
    \〖2\〗 Zhang RH, Dong L, Fu XF, et al. Trends in the prevalence of common retinal and optic nerve diseases in China: an artificial intelligence based national screening. Transl Vis Sci Technol, 2024,13(4):28.
    \〖3\〗 Aref AA, Scott IU, VanVeldhuisen PC, et al. Intraocular pressure-related events after anti-vascular endothelial growth factor therapy for macular edema due to central retinal vein occlusion or hemiretinal vein occlusion: SCORE2 report 16 on a secondary analysis of a randomized clinical trial. JAMA Ophthalmol, 2021,139(12):1285-1291.
    \〖4\〗 Hunt AR, Nguyen V, Arnold JJ, et al.Hemiretinal vein occlusion 12-month outcomes are unique with vascular endothelial growth factor inhibitors: data from the Fight Retinal Blindness! Registry. Br J Ophthalmol, 2023,107(6):842-848.
    \〖5\〗 Campochiaro PA, Hafiz G, Shah SM, et al. Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Mol Ther, 2008,16(4):791-799.
    \〖6\〗 Noma H, Yasuda K, Shimura M. Cytokines and the pathogenesis of macular edema in branch retinal vein occlusion. J Ophthalmol, 2019,2019:5185128.
    \〖7\〗 Patil NS, Mihalache A, Dhoot AS, et al. The impact of residual retinal fluid following intravitreal anti-vascular endothelial growth factor therapy for diabetic macular edema and macular edema secondary to retinal vein occlusion: a systematic review. Ophthalmic Surg Lasers Imaging Retina, 2023,54(1):50-58.
    \〖8\〗 Ayaz Y, Erkan Pota Ç, Ba瘙塂ol i, et al. Anterior segment complications after dexamethasone implantations: real world data. Int Ophthalmol, 2023,43(11):4279-4287.
    \〖9\〗 Ren FM, Gong H, Zhang H, et al. Evaluating the one-year efficacy of combined anti-VEGF and dexamethasone implant treatment for macular edema in retinal vein occlusions. Med Sci Monit, 2023,29:e939277.
    \〖10\〗 Hang A, Feldman S, Amin AP, et al. Intravitreal anti-vascular endothelial growth factor therapies for retinal disorders. Pharmaceuticals(Basel), 2023,16(8):1140.
    \〖11\〗 Qin HF, Shi FJ, Zhang CY, et al. Anti-VEGF reduces inflammatory features in macular edema secondary to retinal vein occlusion. Int J Ophthalmol, 2022,15(8):1296-1304.
    \〖12\〗 Drozdova EA. Long-term outcomes of anti-VEGF therapy for macular edema in retinal vein occlusion. Vestn Oftalmol, 2022,138(3):140-148.
    \〖13\〗 Wang H, Wang CJ, Zhang SC, et al. Impact of anti-VEGF therapy on distinctive retina layers in patients with macular edema secondary to branch retinal vein occlusion. BMC Ophthalmol, 2023,23(1):235.
    \〖14\〗 Hashimoto Y, Okada A, Matsui H, et al. Recent trends in anti-vascular endothelial growth factor intravitreal injections: a large claims database study in Japan. Jpn J Ophthalmol, 2023,67(1):109-118.
    \〖15\〗 Haller JA,Tomaiuolo M, Lucas MM, et al. Disparities in retinal vein occlusion presentation and initiation of anti-VEGF therapy: an academy IRIS® registry analysis. Ophthalmol Retina, 2024,8(7):657-665.
    \〖16\〗 Yuan QZ,Gao YX, Liu YL, et al. Efficacy of single-dose intravitreal dexamethasone implantation for retinal vein occlusion patients with refractory macular edema: a systematic review and meta-analysis. Front Pharmacol, 2022,13:951666.
    \〖17\〗 Limon U,Sezgin Akçay BI. Add-on effect of simultaneous intravitreal dexamethasone to intravitreal bevacizumab in patients with macular edema secondary to branch retinal vein occlusion. J Ocul Pharmacol Ther, 2022,38(2):183-188.
    \〖18\〗 Zhang WY, Liu Y, Sang AM. Efficacy and effectiveness of anti-VEGF or steroids monotherapy versus combination treatment for macular edema secondary to retinal vein occlusion: a systematic review and meta-analysis. BMC Ophthalmol, 2022,22(1):472.
    \〖19\〗 Darabu瘙塂 DM, Munteanu M, Preda MA, et al. The impact of intraocular treatment on visual acuity of patients diagnosed with branch retinal vein occlusions. Healthcare(Basel), 2023,11(10):1414.
    \〖20\〗 李婷婷, 牛彤彤. 玻璃体腔注射雷珠单抗联合筋膜囊注射曲安奈德治疗视网膜静脉阻塞继发黄斑水肿. 中国现代药物应用, 2015,9(2):3-5.
    \〖21\〗 赵通, 张利,尹玥, 等. 玻璃体内注射康柏西普联合后筋膜囊注射曲安奈德对视网膜中央静脉阻塞继发顽固性黄斑水肿患者的治疗效果. 眼科新进展, 2020,40(4):369-372.
    \〖22\〗 Osaka R,Muraoka Y, Nakano Y, et al. One-year results of anti-vascular endothelial growth factor therapy combined with triamcinolone acetonide for macular edema associated with branch retinal vein occlusion. Jpn J Ophthalmol, 2020,64(6):605-612.
    \〖23\〗 Namvar E, Yasemi M, Nowroozzadeh MH, et al. Intravitreal injection of anti-vascular endothelial growth factors combined with corticosteroids for the treatment of macular edema secondary to retinal vein occlusion: a systematic review and meta-analysis. Semin Ophthalmol, 2024,39(1):109-119.
    \〖24\〗 谢佩玲, 张俐娜, 何佳玲, 等. 玻璃体腔注射雷珠单抗联合曲安奈德治疗视网膜静脉阻塞继发黄斑水肿对黄斑区视网膜微循环的影响. 中国药物与临床, 2024,24(19):1247-1251.
    \〖25\〗 阮薏蒙, 姚东伟, 施彦. 雷珠单抗联合地塞米松玻璃体内植入剂治疗视网膜静脉阻塞继发黄斑水肿的临床研究. 中国临床药理学杂志, 2023,39(23):3397-3400.
    \〖26\〗 郝壮, 王珏, 冀帅飞, 等. 抗VEGF药物联合皮质类固醇激素治疗视网膜静脉阻塞性黄斑水肿的Meta分析. 国际眼科杂志, 2021,21(1):99-105.
    \〖27\〗 Shalchi Z, Mahroo O, Bunce C, et al. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion. Cochrane Database Syst Rev, 2020,7(7):CD009510.
    \〖28\〗 Cao W, Cui HP,Biskup E. Combination of grid laser photocoagulation and a single intravitreal ranibizumab as an efficient and cost-effective treatment option for macular edema secondary to branch retinal vein occlusion. Rejuvenation Res, 2019,22(4):335-341.
    \〖29\〗 黄江, 邹维杰, 季晓燕, 等. 抗血管内皮生长因子药物联合与不联合视网膜激光光凝治疗视网膜静脉阻塞合并黄斑水肿疗效比较的系统评价. 中华眼底病杂志, 2021,37(9):715-722.
    \〖30\〗 浦利军, 承伟, 顾晖晖, 等. 不同激光光凝治疗时机联合玻璃体注射康柏西普治疗视网膜中央静脉阻塞继发黄斑水肿的有效性及安全性. 中国老年学杂志, 2020,40(10):2124-2127.
    \〖31\〗 龙河, 刘茂雄, 胡庆华, 等. 577nm阈下微脉冲激光治疗视网膜疾病的研究进展. 国际眼科杂志, 2024,24(5):753-757.
    \〖32\〗 Terashima H, Hasebe H, Okamoto F, et al. Combination therapy of intravitreal ranibizumab and subthreshold micropulse photocoagulation for macular edema secondary to branch retinal vein occlusion: 6-month result. Retina, 2019,39(7):1377-1384.
    \〖33\〗 陈海燕, 史雪辉, 沈冰, 等. 阿柏西普联合阈值下激光治疗缺血型视网膜分支静脉阻塞继发黄斑水肿的临床观察. 中国激光医学杂志, 2023,32(1):13-18,57.
    \〖34\〗 Feng XX, Li YQ, Wu M, et al. Efficacy of subthreshold micropulse laser photocoagulation therapy versus anti-vascular endothelial growth factor therapy for refractory macular edema secondary to non-ischemic branch retinal vein occlusion. J Int Med Res, 2023,51(8):3000605231194462.
    \〖35\〗 张茂菊. 雷珠单抗联合577nm阈值下微脉冲治疗视网膜分支静脉阻塞继发黄斑水肿的临床观察. 中国激光医学杂志, 2021,30(1):56.
    \〖36\〗 McAllister IL, Smithies LA, Chen FK, et al. Two-year efficacy of ranibizumab plus laser-induced chorioretinal anastomosis vs ranibizumab monotherapy for central retinal vein occlusion: a randomized clinical trial. JAMA Ophthalmol, 2018,136(12):1391-1397.
    \〖37\〗 McAllister IL, Smithies LA, Chen FK, et al. Benefits of a laser chorioretinal anastomosis plus ranibizumab vs ranibizumab alone for central retinal vein occlusion: 4-year results. Am J Ophthalmol, 2023,252:101-110.
    \〖38\〗 Stenner AM, Frederiksen KH, Grauslund J. Is there still a role of macular laser treatment in branch retinal vein occlusion in the era of intravitreal injections?Acta Ophthalmol, 2020,98(1):9-21.
    \〖39\〗 杨水平, 陈振文, 郑春荣. 阿柏西普联合全视网膜激光光凝治疗缺血型视网膜中央静脉阻塞伴黄斑水肿的临床价值. 安徽医学, 2023,44(3):252-257.
    \〖40\〗 陈丽丽, 朱成宝. 眼底激光联合IVR治疗RVO-ME患者的疗效观察. 国际医药卫生导报, 2023,29(12):1703-1707.
    \〖41\〗 董阳杰, 潘振楠. 玻璃体腔内注射康柏西普联合黄斑区格栅样激光光凝治疗视网膜分支静脉阻塞继发黄斑水肿的效果. 河南医学研究, 2021,30(30):5603-5606.
    \〖42\〗 李安兴. 康柏西普联合视网膜激光治疗视网膜静脉阻塞继发黄斑水肿的疗效及对其睡眠的影响. 世界睡眠医学杂志, 2024,11(1):30-32.
    \〖43\〗 Parodi MB, Iacono P, Ravalico G. Intravitreal triamcinolone acetonide combined with subthreshold grid laser treatment for macular oedema in branch retinal vein occlusion: a pilot study. Br J Ophthalmol, 2008,92(8):1046-1050.
    \〖44\〗 Pichi F, Specchia C, Vitale L, et al. Combination therapy with dexamethasone intravitreal implant and macular grid laser in patients with branch retinal vein occlusion. Am J Ophthalmol, 2014,157(3):607-615.e1.
    \〖45\〗 Kumar P, Sharma YR, Chandra P, et al. Comparison of the safety and efficacy of intravitreal ranibizumab with or without laser photocoagulation versus dexamethasone intravitreal implant with or without laser photocoagulation for macular edema secondary to branch retinal vein occlusion. Folia Med(Plovdiv), 2019,61(2):240-248.
    \〖46\〗 Shirakata Y, Fukuda K, Fujita T, et al. Pars Plana vitrectomy combined with internal limiting membrane peeling for recurrent macular edema due to branch retinal vein occlusion after antivascular endothelial growth factor treatments. Clin Ophthalmol, 2016,10:277-283.
    \〖47\〗 刘熠赫. 玻璃体切除联合内界膜剥除术治疗继发于视网膜静脉阻塞的黄斑水肿:系统评价与单臂荟萃分析. 东南大学, 2021.
    \〖48\〗 李林, 郭疆, 司马晶, 等. 动静脉鞘膜切开治疗视网膜分支静脉阻塞. 临床眼科杂志, 2012,20(5):426-427.
    \〖49\〗 史伟. 放射状视神经切开术治疗视网膜中央静脉阻塞的可行性及临床价值. 医学综述, 2014,20(20):3795-3796.
    \〖50\〗 Pang JP, Son G, Yoon YH, et al. Combined vitrectomy with intravitreal dexamethasone implant for refractory macular edema secondary to diabetic retinopathy, retinal vein occlusion, and noninfectious posterior uveitis. Retina, 2020,40(1):56-65.
    \〖51\〗 Kumagai K, Ogino N, Fukami M, et al. Vitrectomy for macular edema due to retinal vein occlusion. Clin Ophthalmol, 2019,13:969-984.
    \〖52\〗 Nishida A, Kojima H, Kameda T, et al. Five-year outcomes of pars Plana vitrectomy for macular edema associated with branch retinal vein occlusion. Clin Ophthalmol, 2017,11:369-375.
    \〖53\〗 邓湖广, 蒋鹏飞, 胡艺, 等. 黄斑水肿的病因病机及证治分析. 中医药信息, 2021,38(7):65-68.
    \〖54\〗 苏晶, 刘新泉. 和营利水方联合抗血管内皮生长因子治疗视网膜静脉阻塞性黄斑水肿患者对其眼血流动力学的影响. 世界中西医结合杂志, 2023,18(12):2450-2455.
    \〖55\〗 辛瑞, 黄江丽, 陈晓刚, 等. 自拟活血利水散治疗视网膜静脉阻塞性黄斑水肿的疗效观察. 中医临床研究, 2023,15(10):72-76.
    \〖56\〗 钱小佳, 戚建锋, 叶玉玲, 等. 补肝肾行气化瘀方联合532nm绿激光治疗视网膜分支静脉阻塞黄斑水肿39例. 浙江中医杂志, 2023,58(4):287-288.
    \〖57\〗 南炳辉. 剔络化瘀方联合激光治疗缺血型视网膜分支静脉阻塞黄斑水肿临床观察. 实用中医药杂志, 2019,35(3):334-336.
    \〖58\〗 刘艳琳. 自拟黄斑水肿消解汤联合雷珠单抗及激光治疗视网膜静脉阻塞性黄斑水肿的临床观察. 现代中西医结合杂志, 2021,30(6):639-642.
    \〖59\〗 刘向芹. 行气活血健脾利水方联合小剂量曲安奈德玻璃体腔注射治疗视网膜静脉阻塞性黄斑水肿临床研究. 现代中西医结合杂志, 2021,30(3):282-286.
    \〖60\〗 高辉, 李焕丽, 庞荣. 复方樟柳碱联合抗VEGF药物治疗视网膜分支静脉阻塞黄斑水肿. 国际眼科杂志, 2019,19(2):323-325.
    \〖61\〗 Obeid A, Hsu J,Ehmann D, et al. Topical dorzolamide-timolol with intravitreous anti-vascular endothelial growth factor for retinal vein occlusion: a pilot study. Retin Cases Brief Rep, 2021,15(2):120-126.
    \〖62\〗 Yan Y, Chen Y, Liu ZS. Significant vision improvement and successful prevention of recurrence by electroacupuncture inhemiretinal vein occlusion combined with macular edema: a case report. Medicine(Baltimore), 2021,100(50):e28202.
    \〖63\〗 Fekri S, Nourinia R, Rahimi-Ardabili B, et al. Combined intravitreal injection of bevacizumab and a ROCK inhibitor(fasudil)for refractory macular edema secondary to retinal vein occlusion: a pilot study. Int J Retina Vitreous, 2022,8(1):37.
    \〖64\〗 中华医学会眼科学分会眼底病学组, 中国医师协会眼科医师分会眼底病专业委员会. 中国视网膜静脉阻塞临床诊疗路径专家共识. 中华眼底病杂志, 2024,40(3):175-185.
    \〖65\〗 Stern HD,Hussain RM. KSI-301: an investigational anti-VEGF biopolymer conjugate for retinal diseases. Expert Opin Investig Drugs, 2022,31(5):443-449.
    \〖66\〗 Nguyen H, Lee SJ, Li Y. Selective activation of thewnt-signaling pathway as a novel therapy for the treatment of diabetic retinopathy and other retinal vascular diseases. Pharmaceutics, 2022,14(11):2476.
您是第 8810011 位访问者
主管单位：陕西省卫生健康委员会
主办单位：中华医学会西安分会
地址：陕西省西安市碑林区雁塔路北段8号万达广场2栋1单元11707室
传真：029-82245172 电话：029-85205906/82245172
Email：ijo.2000@163.com,ijo2000@126.com
国际眼科杂志 ® 2025 版权所有   CC BY-NC-ND 4.0 适用于所有开放获取内容